Gingko mihuan

Drug Profile

Gingko mihuan

Alternative Names: Gingko Mihuan - Tianyin Pharmaceuticals; Gingko Mihuan - TPI; GMOL

Latest Information Update: 29 Dec 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tianyin Pharmaceutical
  • Class Cardiovascular therapies; Flavonoids; Glycosides; Terpenes; Traditional-Chinese-medicine
  • Mechanism of Action Antioxidants; Platelet activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Angina pectoris; Cardiovascular disorders; Cerebral infarction; Cerebral ischaemia; Coronary disorders; Memory disorders; Neurological disorders; Stroke

Most Recent Events

  • 24 Dec 2014 Tianyin Pharmaceuticals and an undisclosed company entered into a research and development agreement for formulation varieties of gingko mihuan
  • 17 Jul 2012 Launched for Angina pectoris in China (PO) before July 2012
  • 17 Jul 2012 Launched for Cardiovascular disorders in China (PO) before July 2012
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top